MX2020012445A - Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos. - Google Patents
Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos.Info
- Publication number
- MX2020012445A MX2020012445A MX2020012445A MX2020012445A MX2020012445A MX 2020012445 A MX2020012445 A MX 2020012445A MX 2020012445 A MX2020012445 A MX 2020012445A MX 2020012445 A MX2020012445 A MX 2020012445A MX 2020012445 A MX2020012445 A MX 2020012445A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- antigen receptors
- car
- linker domains
- modified linker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018901782A AU2018901782A0 (en) | 2018-05-21 | Chimeric Antigen Receptors with Modified Linker Domain and uses thereof | |
| PCT/AU2019/050487 WO2019222796A1 (en) | 2018-05-21 | 2019-05-20 | Chimeric antigen receptors with modified linker domains and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012445A true MX2020012445A (es) | 2021-02-09 |
Family
ID=68615492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012445A MX2020012445A (es) | 2018-05-21 | 2019-05-20 | Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos. |
Country Status (11)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121539B2 (en) | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| EP4045648A4 (en) * | 2019-10-15 | 2023-11-22 | The Regents of The University of California | Transplanted cell protection via fc sequestration |
| CN111944062B (zh) * | 2019-12-09 | 2023-11-07 | 深圳市体内生物医药科技有限公司 | 一种识别Fc片段的嵌合抗原受体及其应用 |
| KR20220140800A (ko) * | 2020-02-12 | 2022-10-18 | 에스에이비, 엘엘씨 | 항-흉선세포 글로불린 |
| EP4204005A1 (en) | 2020-08-31 | 2023-07-05 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof |
| CA3211323A1 (en) * | 2021-03-11 | 2022-09-15 | Patrick Schlegel | Novel cell therapy system |
| JP2024532482A (ja) * | 2021-09-01 | 2024-09-05 | バイオセプター (オースト) プロプライエタリー・リミテッド | 免疫活性を刺激するための方法および組成物 |
| EP4476267A4 (en) * | 2022-02-11 | 2026-01-07 | Fred Hutchinson Cancer Center | CHIMERIC ANTIGENIC RECEPTORS BINDING TO STEAP1 |
| JP2025531675A (ja) * | 2022-09-14 | 2025-09-25 | バイオセプター (オースト) プロプライエタリー・リミテッド | 操作された免疫細胞の富化 |
| CN120187461A (zh) * | 2022-09-14 | 2025-06-20 | 生物权威(澳大利亚)有限责任公司 | 免疫细胞的体内检测 |
| US20260085104A1 (en) * | 2022-09-14 | 2026-03-26 | Biosceptre (Aust) Pty Ltd | Methods of detecting immune cells |
| WO2026035817A1 (en) * | 2024-08-06 | 2026-02-12 | Board Of Regents, The University Of Texas System | Suicide egfr-iii compositions and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4940661A (en) | 1984-05-17 | 1990-07-10 | Genentech, Inc. | Metallothionein transcription control sequences and use thereof |
| US5512483A (en) | 1993-05-21 | 1996-04-30 | Mcgill University | Expression vectors responsive to steroid hormones |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| JPH11506319A (ja) | 1995-05-26 | 1999-06-08 | ゼネカ・リミテッド | エクジソンレセプターを含む遺伝子スイッチ |
| US5851796A (en) | 1995-06-07 | 1998-12-22 | Yale University | Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes |
| WO2001020155A1 (fr) * | 1999-09-16 | 2001-03-22 | Liangqi Zhang | Membrane de reduction de pression pour carburateur |
| WO2003020762A1 (en) | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| DK1751181T3 (da) | 2004-06-02 | 2012-11-26 | Adalta Pty Ltd | BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER |
| US20100036101A1 (en) | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| WO2008043145A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional p2x7 receptor |
| JP5670192B2 (ja) | 2007-09-14 | 2015-02-18 | バイオセプター・インターナショナル・リミテッド | 新規p2x7エピトープ |
| AU2009266430B2 (en) | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| EP3395832B1 (en) | 2009-08-20 | 2021-11-24 | Biosceptre (Aust) Pty Ltd | Anti p2x7 receptor antibodies and fragments thereof |
| EP2516470B1 (en) | 2009-12-24 | 2018-02-07 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
| EP3115373B1 (en) * | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| WO2012073048A2 (en) | 2010-12-03 | 2012-06-07 | Cyclogenix Ltd | Binding peptides i |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| ES2738705T3 (es) * | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| CN107429253B (zh) * | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| EP3250611B1 (en) * | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN114634569B (zh) * | 2016-04-15 | 2024-08-20 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| WO2018017649A1 (en) * | 2016-07-19 | 2018-01-25 | Unum Therapeutics Inc. | Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| EP3315511A1 (en) * | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
-
2019
- 2019-05-20 AU AU2019275479A patent/AU2019275479B2/en active Active
- 2019-05-20 JP JP2020565274A patent/JP2021524248A/ja active Pending
- 2019-05-20 KR KR1020207033662A patent/KR20210013691A/ko not_active Ceased
- 2019-05-20 US US17/057,060 patent/US20220089718A1/en active Pending
- 2019-05-20 MX MX2020012445A patent/MX2020012445A/es unknown
- 2019-05-20 CA CA3099712A patent/CA3099712A1/en active Pending
- 2019-05-20 SG SG11202010451QA patent/SG11202010451QA/en unknown
- 2019-05-20 CN CN201980034413.2A patent/CN112166193A/zh active Pending
- 2019-05-20 EP EP19808128.3A patent/EP3797164A4/en active Pending
- 2019-05-20 WO PCT/AU2019/050487 patent/WO2019222796A1/en not_active Ceased
- 2019-05-20 BR BR112020023489A patent/BR112020023489A8/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3797164A4 (en) | 2022-03-02 |
| SG11202010451QA (en) | 2020-11-27 |
| CN112166193A (zh) | 2021-01-01 |
| CA3099712A1 (en) | 2019-11-28 |
| AU2019275479B2 (en) | 2022-12-08 |
| BR112020023489A2 (pt) | 2021-03-30 |
| EP3797164A1 (en) | 2021-03-31 |
| WO2019222796A1 (en) | 2019-11-28 |
| AU2019275479A1 (en) | 2020-11-19 |
| KR20210013691A (ko) | 2021-02-05 |
| BR112020023489A8 (pt) | 2022-12-20 |
| JP2021524248A (ja) | 2021-09-13 |
| US20220089718A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020023489A8 (pt) | Receptores de antígenos quiméricos com domínios de ligação modificados e usos dos mesmos | |
| PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| CU24475B1 (es) | Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| IL272302A (en) | Chimeric antigen receptor mediated cell targeting | |
| MX2017006233A (es) | Celula. | |
| GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| PE20211299A1 (es) | Receptores de antigeno quimericos dirigidos a cd70 | |
| MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
| BR112018067698A2 (pt) | células modificadas para imunoterapia | |
| MX2016015834A (es) | Receptores quiméricos de antigeno que tienen como diana a cd-19. | |
| MX420947B (es) | Constructos que reconocen específicamente glipicano 3 y usos de estos. | |
| UY40733A (es) | Un constructo de anticuerpo que comprende al menos tres dominios | |
| MX2017003645A (es) | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. | |
| CL2018000270A1 (es) | Constructos de anticuerpo para cd70 y cd3. | |
| CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
| CO2019013654A2 (es) | Receptores de antígenos quiméricos que se dirigen a flt3 | |
| MX2019009346A (es) | Variantes de polipeptidos y usos de los mismos. | |
| CL2018002063A1 (es) | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t | |
| CL2017000110A1 (es) | Moléculas con especificidad para dc79 y cd22 | |
| BR112019014986A2 (pt) | anticorpo que alveja bcma e uso do mesmo | |
| UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
| CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| MX2017009182A (es) | Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas. | |
| MX2015010836A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado. |